Alina Ciammaichella

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers.

Discovery and Preclinical Characterization of I-0436650, a Selective SHP2 Allosteric Inhibitor for RAS-Driven Cancers.

Journal: Journal of medicinal chemistry
Published: April 13, 2026

A patent review of SHP2 allosteric inhibitors (2018-present).

A patent review of SHP2 allosteric inhibitors (2018-present).

Journal: Expert opinion on therapeutic patents
Published: June 06, 2024

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.

Discovery of a Novel Series of Imidazopyrazine Derivatives as Potent SHP2 Allosteric Inhibitors.

Journal: ACS medicinal chemistry letters
Published: October 21, 2022

Identification of HSPB8 modulators counteracting misfolded protein accumulation in neurodegenerative diseases.

Identification of HSPB8 modulators counteracting misfolded protein accumulation in neurodegenerative diseases.

Journal: Life sciences
Published: August 01, 2022

Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated Neurodegeneration.

Cyclic Phosphopantothenic Acid Prodrugs for Treatment of Pantothenate Kinase-Associated Neurodegeneration.

Journal: Journal of medicinal chemistry
Published: December 15, 2020

Turnover rate of coenzyme A in mouse brain and liver.

Turnover rate of coenzyme A in mouse brain and liver.

Journal: PloS one
Published: November 11, 2020

Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.

Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.

Journal: Bioorganic & medicinal chemistry letters
Published: February 24, 2020

Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.

Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides.

Journal: ACS medicinal chemistry letters
Published: October 31, 2018

Rhodium Porphyrin Bound to a Merrifield Resin as Heterogeneous Catalyst for the Cyclopropanation Reaction of Olefins.

Rhodium Porphyrin Bound to a Merrifield Resin as Heterogeneous Catalyst for the Cyclopropanation Reaction of Olefins.

Journal: Molecules (Basel, Switzerland)
Published: February 04, 2016

Aromatic core extension in the series of N-cyclic bay-substituted perylene G-quadruplex ligands: increased telomere damage, antitumor activity, and strong selectivity for neoplastic over healthy cells.

Aromatic core extension in the series of N-cyclic bay-substituted perylene G-quadruplex ligands: increased telomere damage, antitumor activity, and strong selectivity for neoplastic over healthy cells.

Journal: ChemMedChem
Published: July 16, 2012

A π-stacked porphyrin-fullerene electron donor-acceptor conjugate that features a surprising frozen geometry.

A π-stacked porphyrin-fullerene electron donor-acceptor conjugate that features a surprising frozen geometry.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: June 25, 2012
Showing 1-11 of 11

Last Updated: 09/26/2026